Yale Cancer Center is pleased to announce that Sarah Goldberg, MD, MPH, associate professor of internal medicine (medical oncology), has been awarded one of two research grants from the Lung Cancer Research Foundation (LCRF), in collaboration with Bayer Pharmaceuticals. The grant is focused on innovative strategies to advance the understanding and management of lung cancers harboring HER2 mutations and/or other HER2 alterations.
Goldberg conducts clinical and translational research on lung cancer with a focus on investigating biomarkers and novel treatment strategies in non-small cell lung cancer. Her specific research interests include EGFR mutation positive lung cancer, immunotherapeutics for lung cancer, and brain metastases. Her research project, entitled "Stratifying and Personalizing for HER2 Mutated Lung Cancers" addresses important mechanistic questions and developmental therapeutics across the care continuum for HER2-mutant NSCLC, with the potential to improve patient outcomes
The Lung Cancer Research Foundation® is the leading nonprofit organization focused on funding innovative, high-reward research with the potential to extend survival and improve quality of life for people with lung cancer. Xiuning Le, MD, PhD, from the University of Texas MD Anderson Cancer Center received the second award. Each will receive $500,000 over two years for their projects.